Radioiodine therapy for well-differentiated thyroid carcinoma;Radiojodtherapie beim differenzierten Schilddrusenkarzinom

Zentralblatt fur Chirurgie

Volumn 122, Issue 4, 1997, Pages 266-273

  Schicha, H ^a   Dietlein, M ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

ablation; differentiated thyroid carcinoma; distant metastases; radioiodine therapy; side effects

Indexed keywords

RADIOACTIVE IODINE;

ARTICLE; CANCER RECURRENCE; CLINICAL PROTOCOL; CLINICAL TRIAL; DRUG EFFICACY; FOLLOW UP; HUMAN; METASTASIS; PROPHYLAXIS; STANDARDIZATION; THYROID CARCINOMA; ADJUVANT THERAPY; ADOLESCENT; ADULT; CANCER STAGING; MALE; MIDDLE AGED; MINIMAL RESIDUAL DISEASE; MULTIMODALITY CANCER THERAPY; PATHOLOGY; REVIEW; THYROID TUMOR; THYROIDECTOMY; TUMOR RECURRENCE;

ADOLESCENT; ADULT; COMBINED MODALITY THERAPY; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEOPLASM, RESIDUAL; RADIOTHERAPY, ADJUVANT; THYROID NEOPLASMS; THYROIDECTOMY;

EID: 0030905502     PISSN: 0044409X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Ain K B (1995) Papillary thyroid carcinoma. Endocrinol Metab Clinics North America 24: 711-761
2. Baldet L, Manderscheid JC, Glinoer D, Jaffiol C (1989) The management of differentiated thyroid cancer in Europe in 1988. Acta Endocrinologica (Cph) 120: 547-558
3. Böttger T, Klupp J, Gabbert HE, Junginger T (1991) Prognostisch relevante Faktoren beim papillären Schilddrüsenkarzinom. Med Klin 86: 76-82
4. Bushnell DL, Boles MA, Kaufman GE, Wadas MA. Barnes WE (1992) Complications, sequela and dosimetry of iodine-131 therapy for thyroid carcinoma. J Nucl Med 33: 2214-2221
5. Casara D, Rubello D, Saladini G, Piotto A, Pelizzo MR, Girelli ME. Busnardo B (1993) Pregnancy after high therapeutic doses of iodine-131 in differentiated thyroid cancer: potential risks and recommendations. Eur J Nucl Med 20: 192-194
6. Casara D, Rubello D, Saladini G, Masarotto G, Favero A, Girelli ME. Busnardo B (1993) Different features of pulmonary metastases in differentiated thyroid cancer: natural history and multivariate statistical analysis of prognostic variables. J Nucl Med 34: 1626-1631
7. Cole ES, Lee K, Lauziere K, Kelton C, Chappel S, Weintraub B, Ferrara D, Peterson P, Bernasconi R, Edmunds T, Richards S, Dickrell L, Kleeman JM, McPherson JM, Pratt BM (1993) Recombinant human thyroid stimulating hormone: development of a biotechnology product for detection of metastatic lesions of thyroid carcinoma. Bio/Technology 11: 1014-1024
8. Dinneen SF, Valimaki MJ, Bergstralh EJ, Goellner JR, Gorman CA, Hay ID (1995) Distant metastases in papillary thyroid carcinoma: 100 cases observed at one institution during 5 decades. J Clin Endocrinol Metab 80: 2041-2045
9. Dottorini ME, Lomuscio G, Mazzucchelli L, Vignati A, Colomgo L (1995) Assessment of female fertility and carcinogenesis after iodine-131 therapy for differentiated thyroid carcinoma J Nucl Med 36: 21-27
10. Dottorini ME (1996) Genetic risk assessment after iodine-131 exposure: an opportunity and obligation for nuclear medicine. J Nucl Med 37: 612-615
11. Edmonds CJ. Smith T (1986) The long-term hazards of the treatment of thyroid cancer with radioiodine. Brit J Radiol 59: 45-51
12. Farahati J, Reiners C, Stuschke M, Müller SP, Stüben G, Sauerwein W, Sack H (1996) Differentiated thyroid cancer. Impact of adjuvant external radiotherapy in patients with perithyroidal tumor infiltration (stage pT4). Cancer 77, 172-180
13. Georgi P, Emrich D, Heidenreich P, Moser E, Reiners C, Schicha H (1992) Radiojodtherapie des differenzierten Schilddrüsenkarzinoms. Nuklearmedizin 31: 151-153
14. Georgi P (1992) Übereinstimmungen und Diskrepanzen bei der Radtojodtherapie des differenzierten Schilddrüsenkarzinoms. Nuklearmedizin 31: 145-150
15. Grebe SKG, Hay ID (1995) Follicular thyroid cancer. Endocrinol Metab Clinics North America 24: 761-801
16. Günter HH, Schober O, Schwarzrock R, Hundeshagen H (1987) Hȧmatologische Langzeitveränderungen nach Radio-jodtherapie des Schilddrüsenkarzinoms. Strahlentherapie und Onkologie 163: 475-485
17. Günter HH, Junker D, Schober O, Hundeshagen H (1987) Dosimetrie des hȧmatopoetischen Systems bei der Radiojodtherapie des Schilddrüsenkarzinoms. Strahlentherapie und Onkologie 163: 185-191
18. Hay ID, Bergstralh EJ, Goellner JR, Ebersold JR, Grand CS (1993) Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery 114: 1050-1058
19. Kemmer W (1992) Die Neufassung der Richtlinie Strahlenschutz in der Medizin. H. Hoffmann GmbH Verlag Berlin
20. Kim CK, Tse K, Pedro EX, Alavi A (1994) Influence of various scanning doses on subsequent 1-131 ablation of thyroid remnants. J Nucl Med 35: 14 P
21. Lerch H, Kuwert T, Sauer HB, Schober O (1996) Survival of differentiated thyroid carcinoma studied in 500 patients. J Clin Oncol in press
22. Maxon HR, Thomas SR, Hertzberg VS, Kereiakes JG, Chen IW, Sperling MI, Saenger EL (1983) Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer. New Engl J Med 309: 937-941
23. Maxon HR, Englaro EE, Thomas SR, Hertzberg VS, Hinne-feld JD, Chen LS, Smitz H, Cummings D, Aden MD (1992) Radioiodine-131 therapy for well-differentiated thyroid cancer - a quantitative radiation dosimetric approach: outcome and validation in 85 patients. J Nucl Med 33, 1132-1135
24. Mazzaferri EL, Jhiang SM (1994) Longterm impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Amer J Med 97: 418-428
25. Mazzaferri EL (1994) Treating high thyroglobulin with radioiodine: a magic bullet or a shot in the dark? J Clin Endocrinol Metab 80: 1485-1487
26. Meier CA, Braverman LE, Ebner SA, Veronikis I, Daniels GH, Ross DS, Deraska DJ. Davies TF, Valentine M, DeGroot LJ, Curran P, McEllin K, Reynolds J, Robbins J, Weintraub BD (1994) Diagnostic use of recombinant human thyrotropin in patients with thyroid carcinoma (phase I/II study). J Clin Endocrinol Metab 78: 188-196
27. Park HM, Perkins OW, Edmondson JW, Schnute RB, Manatunga A (1994) Influence of diagnostic radioiodines on the uptake of ablative dose of iodine-131. Thyroid 4: 49-54
28. Patwardhan N, Cataldo T, Braverman LE (1994) Surgical management of the patient with papillary cancer. Endocrine Surgery 75: 449-464
29. Pineda JD, Lee T, Ain K, Reynolds JC, Robbins J (1995) Iodine-131 therapy for thyroic cancer patients with elevated thyroglobulin and negative diagnostic scan. J Clin Endocrinol Metab 80: 1488-1492
30. Puskas C, Sciuk J, Schober O (1990) Somatische Risiken der hochdosierten Radiojodtherapie. Der Nuklearmediziner 5: 295-304
31. Reiners C (1991) Stochastische Risiken der I-131-Therapie des Schilddrüsenkarzinoms. Der Nuklearmediziner 1: 44-51
32. Robbins J (1994) Approaches to the treatment of highrisk thyroid cancer. Thyroid 4: 385-387
33. Ruegemer JJ, Hay ID, Bergstralh EJ, Ryan JJ, Offord KP, Gorman CA (1988) Distant metastases in differentiated thyroid carcinoma: a multivariate analysis of prognostic variables. J Clin Endocrinol Metab 67: 501-508
34. Samaan NA, Schultz PN, Hickey RC, Goepfert H, Haynie TP, Johnston DA, Ordonez NG (1992) The results of various modalities of treatment of well differentiated thyroid carcinoma: a retrospective review of 1599 patients. J Clin Endocrinol Metab 75: 714-720
35. Samuel AM, Rajashekharrao B (1994) Radioiodine therapy for well-differentiated thyroid cancer: a quantitative dosimetric evaluation for remnant thyroid ablation after surgery. J Nucl Med 35: 1944-1950
36. Sarkar SD, Beierwaltes WH, Gill SP, Cowley BJ (1976) Subsequent fertility and birth histories of children and adolescents treated with 131I for thyroid cancer. J Nucl Med 17: 460-464
37. Schlumberger M, Tubiana M, De Vathaire F, Hill C, Gardet P, Travagli JP, Fragu P, Lumbroso J, Caillou B, Parmentier C (1986) Longterm results of treatment of 283 patients with lung and bone metastases from differentiated thyroid carcinoma. J Clin Endocrinol Metab 63: 960-967
38. Schlumberger M, Challeton C, De Vathaire F, Travagli JP, Gardet P, Lumbroso JD, Francese C, Fontaine F, Ricard M, Parmentier C (1996) Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma. J Nucl Med 37: 598-605
39. Schlumberger M, De Vathaire F, Ceccarelli C, Delisle MJ, Francese C, Couette JE, Pinchera A, Parmentier C (1996) Exposure to radioactive iodine-131 for scintigraphy or therapy does not preclude pregnancy in thyroid cancer patients. J Nucl Med 37: 606-612
40. Schober O, Günter HH, Schwarzrock R, Hundeshagen H (1987) Hämatologische Langzeitveränderungen bei der Ra- diojodtherapie des Schilddrüsenkarzinoms. Strahlentherapie und Onkologie 63: 464-474
41. Schümichen C, Schmitt E, Scheuffele C, Blattmann H, Pauli-Hamasch C (1983) Einfluß des Therapiekonzepts auf die Prognose des Schilddrüsenkarzinoms. Nuklearmedizin 22: 97-105
42. Solomon BL, Wartofsky L, Burman KD (1996) Current trends in the management of well differentiated papillary thyroid carcinoma. J Clin Endocrinol Metab 81: 333-339
43. Sweeney DC, Johnston GS (1995) Radioiodine therapie for thyroid cancer. Endocrinol Metab Clinics North America 24: 803-839
44. Wellner U, Schicha H (1996) Der Einfluß physiologischer und pharmakologischer lodmengen auf den 131I-Uptake der Schilddrüse - Eine Modellrechnung. Nuklearmedizin (im Druck)